Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published July 2010
  • Article
  • Info & Metrics
  • PDF
Loading

Metronomic Gemcitabine Inhibits Pancreatic Cancer

Tran Cao et al., Page 2068

Tran Cao and colleagues evaluated the efficacy of metronomic gemcitabine against metastasis formation in a highly-aggressive, RFP-labeled orthotopic nude mouse model of human pancreatic cancer. Metronomic gemcitabine reduced the spontaneous development of both solid metastases and ascites and significantly prolonged survival of mice without overt toxicity. These results suggest the clinical potential of adjuvant metronomic gemcitabine for the treatment of pancreatic cancer.

MK-2206 Sensitizes Tumors to Chemotherapy

Hirai et al., Page 1956

Akt lies at a critical signaling node downstream of PI3K and is important in promoting cell survival and inhibiting apoptosis. Increased Akt signaling is associated with reduced sensitivity to cytotoxic agents or receptor tyrosine kinase inhibitors in preclinical models. The effect of a novel allosteric Akt inhibitor, MK-2206, was evaluated in combination with several anticancer agents. MK-2206 showed synergistic antitumor activities in combination with erlotinib, lapatinib, and cytotoxic agents, suggesting Akt inhibition may augment the efficacy of anticancer agents. MK-2206 (now in Phase I) is a promising agent to treat cancer patients who receive these cytotoxic and/or molecular targeted agents.

SCC Apoptosis Induction by PS-341 and HDAC Inhibitors

Kim et al., Page 1977

Head and neck squamous cell carcinoma (HNSCC) is relatively resistant to chemotherapy-mediated apoptosis and frequently develops chemoresistance. Thus, improvement on conventional therapy is urgently needed to effectively treat HNSCC. In this study, Kim and colleagues found that the histone deacetylase inhibitor trichostatin A (TSA) significantly enhanced apoptosis in HNSCC induced by PS-341 (also known as bortezomib) in vitro and improved PS-341-mediated inhibition of HNSCC tumor growth in nude mice. Mechanistically, TSA increased PS-341-induced Noxa expression and caspase activation in HNSCC cells. These results provide an important rationale for the usage of a combination of both agents in patients with HNSCC.

Methylseleninic Acid Enhances Anti-Androgen Efficacy

Liu et al., Page 2016

The development of castrationresistant prostate cancer after androgen deprivation therapy remains the major challenge in the treatment of advanced prostate cancer. Liu and colleagues showed that methylseleninic acid, an agent that effectively reduces androgen receptor abundance, significantly enhanced the cancer-killing efficacy of anti-androgen. Downregulation of telomerase as a result of androgen receptor signaling suppression is critically involved in mediating the combination effect. The findings indicate that methylseleninic acid in combination with anti-androgen could represent a viable approach to improve the therapeutic outcome of androgen deprivation therapy and that telomerase could serve as a tumor-specific biomarker to monitor the efficacy.

  • ©2010 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 9 (7)
July 2010
Volume 9, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther July 1 2010 (9) (7) 1929;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther July 1 2010 (9) (7) 1929;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Metronomic Gemcitabine Inhibits Pancreatic Cancer
    • MK-2206 Sensitizes Tumors to Chemotherapy
    • SCC Apoptosis Induction by PS-341 and HDAC Inhibitors
    • Methylseleninic Acid Enhances Anti-Androgen Efficacy
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement